Sanofi (NASDAQ:SNY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Sanofi (NASDAQ:SNY) from a hold rating to a buy rating in a report released on Saturday,Wall Street Zen reports.

A number of other equities research analysts also recently issued reports on SNY. Weiss Ratings downgraded shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Morgan Stanley set a $49.00 price objective on Sanofi in a research note on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $49.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $44.36 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. Sanofi has a one year low of $40.89 and a one year high of $52.68. The firm has a market capitalization of $107.55 billion, a P/E ratio of 23.23, a PEG ratio of 1.37 and a beta of 0.35. The company’s fifty day moving average is $43.72 and its two-hundred day moving average is $44.77.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, July 30th. The company reported $2.41 EPS for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The firm had revenue of $13.36 billion during the quarter. During the same quarter last year, the business earned $3.24 EPS. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. Analysts forecast that Sanofi will post 5.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Hedge funds have recently added to or reduced their stakes in the business. Physician Wealth Advisors Inc. lifted its holdings in shares of Sanofi by 180.5% in the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after purchasing an additional 379 shares in the last quarter. Leonteq Securities AG increased its stake in shares of Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after purchasing an additional 297 shares in the last quarter. Western Wealth Management LLC acquired a new position in shares of Sanofi during the 1st quarter worth approximately $29,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Sanofi during the 3rd quarter worth approximately $29,000. Finally, Palisade Asset Management LLC purchased a new stake in Sanofi in the 3rd quarter valued at approximately $30,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.